High-grade glioma in very young children: a rare and particular patient population
Open Access
- 14 June 2017
- journal article
- review article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (38), 64564-64578
- https://doi.org/10.18632/oncotarget.18478
Abstract
In the past years, pediatric high-grade gliomas (HGG) have been the focus of several research articles and reviews, given the recent discoveries on the genetic and molecular levels pointing out a clinico-biological uniqueness of the pediatric population compared to their adult counterparts with HGG. On the other hand, there are only scarce data about HGG in very young children (below 3 years of age at diagnosis) due to their relatively low incidence. However, the few available data suggest further distinction of this very rare subgroup from older children and adults at several levels including their molecular and biological characteristics, their treatment management, as well as their outcome. This review summarizes and discusses the current available knowledge on the epidemiological, neuropathological, genetic and molecular data of this subpopulation. We discuss these findings and differences compared to older patients suffering from the same histologic disease. In addition, we highlight the particular clinical and neuro-radiological findings in this specific subgroup of patients as well as their current management approaches and treatment outcomes.Keywords
This publication has 88 references indexed in Scilit:
- K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomasActa Neuropathologica, 2012
- Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomasNature Genetics, 2012
- Altered Telomeres in Tumors with ATRX and DAXX MutationsScience, 2011
- Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology GroupNeuro-Oncology, 2011
- Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancerMolecular Cancer, 2010
- A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade GliomasClinical Cancer Research, 2010
- Implication of snoRNA U50 in human breast cancerJournal of Genetics and Genomics, 2009
- Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor StudyJNCI Journal of the National Cancer Institute, 2009
- SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancerHuman Molecular Genetics, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005